MaxCyte

MaxCyte, Inc. specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes.

MaxCyte, Inc. specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes of therapeutics for a range of chronic and acute diseases. It provides MaxCyte STX, a scalable transfection system for the scalable and reagent-free (co) transfection of primary cells, stem cells, and cell lines involved in the areas of cell-based assays for content screening, preclinical protein production, and small molecule drug discovery.MaxCyte, Inc. was formerly known as TheraMed, Inc. and changed its name to MaxCyte, Inc. in October 2001. The company was founded in 1999 and is based in Gaithersburg, Maryland.